Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is characterized by immune system dysfunction and is clinically heterogeneous, exhibiting renal, dermatological, neuropsychiatric, and cardiovascular symptoms. Clinical and physiological assessment is usually inadequate for diagnosing and assessing pathophysiological processes in SLE. Clinical and immunological biomarkers could play a critical role in improving diagnosis, assessment, and ultimately, control of SLE. This article reviews clinical and immunological biomarkers that could diagnose and monitor disease activity in SLE, with and without organ-specific injury. In addition, novel SLE biomarkers that have been discovered through omics research are also reviewed.

Automated summary

Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease characterized by immune dysfunction. Clinical and immunological biomarkers are crucial for diagnosing, assessing, and controlling SLE, including novel biomarkers discovered through omics research.